Publications by authors named "Kimberly A Struble"

Claim this Profile
L
Long-Acting Formulations for the Prevention and Treatment of Human Immunodeficiency Virus (HIV)-1 Infection: Strategic Leveraging and Integration of Multidisciplinary Knowledge to Advance Public Health.
Vikram Arya, Aimee C Hodowanec, Stephanie B Troy, Kimberly A Struble

Clin Infect Dis· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations and challenges in developing novel long-acting antiretrovirals modalities for treatment and prevention of HIV-1 infection: a regulatory perspective.
Mario R Sampson, Stephanie B Troy, Yodit Belew, Vikram Arya, Kimberly A Struble

Curr Opin HIV AIDS· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint.
Sarita D Boyd, Mario R Sampson, Prabha Viswanathan, Kimberly A Struble, Vikram Arya

AIDS· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Why did the FDA approve efavirenz 800 mg when co-administered with rifampin?
Jiang Liu, Kirk M Chan-Tack, Pravin Jadhav, Shirley Seo, Sarah M Robertson, Kimberly A Struble

Int J Clin Pharmacol Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to Tan et al.
David T Kuhar, Kimberly A Struble, David K Henderson

Infect Control Hosp Epidemiol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis.
David T Kuhar, David K Henderson, Kimberly A Struble, Walid Heneine, Vasavi Thomas

Infect Control Hosp Epidemiol· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Scientific considerations for pharmacoenhancers in antiretroviral therapy.
Vikram Arya, Sarah M Robertson, Kimberly A Struble, Jeffrey S Murray

J Clin Pharmacol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meta-analysis of gender differences in efficacy outcomes for HIV-positive subjects in randomized controlled clinical trials of antiretroviral therapy (2000-2008).
Guoxing Greg Soon, Min Min, Kimberly A Struble, Kirk M Chan-Tack, Thomas Hammerstrom

AIDS Patient Care STDS· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Running a tightrope: regulatory challenges in the development of antiretrovirals.
Lisa K Naeger, Kimberly A Struble, Jeffrey S Murray, Debra B Birnkrant

Antiviral Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV clinical trial design for antiretroviral development: moving forward.
Kirk M Chan-Tack, Kimberly A Struble, Nathalie Morgensztejn, Jeffrey S Murray, Roy Gulick

AIDS· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intracranial hemorrhage and liver-associated deaths associated with tipranavir/ritonavir: review of cases from the FDA's Adverse Event Reporting System.
Kirk M Chan-Tack, Kimberly A Struble, Debra B Birnkrant

AIDS Patient Care STDS· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory issues in developing new HIV protease inhibitors: risks and benefits.
Kimberly A Struble, Kirk M Chan-Tack, Guoxing Greg Soon

Curr Opin HIV AIDS· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A regulatory perspective on the role of drug interactions in antiretroviral drug development.
Kimberly A Struble, Kellie Schoolar Reynolds

Curr Opin HIV AIDS· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Are literature references sufficient for dose recommendations? An FDA case study of efavirenz and rifampin.
Jennifer L DiGiacinto, Kirk M Chan-Tack, Sarah M Robertson, Kellie S Reynolds, Kimberly A Struble

J Clin Pharmacol· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Kirk M Chan-Tack, Melissa M Truffa, Kimberly A Struble, Debra B Birnkrant

AIDS· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Food and Drug Administration analysis of tipranavir clinical resistance in HIV-1-infected treatment-experienced patients.
Lisa K Naeger, Kimberly A Struble

AIDS· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Lisa K Naeger, Kimberly A Struble

AIDS· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services.
Dawn K Smith, Lisa A Grohskopf, Roberta J Black, Judith D Auerbach, Fulvia Veronese, Kimberly A Struble

MMWR Recomm Rep· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis